OliX Pharma Amends Capital Increase Details
올릭스
226950
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2414
Risk-adjusted indicator based on 2414 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • New Shares (Common Stock): 670,000 Shares (Revised from 740,367 Shares)
- • Operating Funds: 100,231,330,000 KRW (Revised from 110,758,162,833 KRW)
- • Listing Date: July 15, 2026 (Revised from July 17, 2026)
- • R&D Expenses (2026-2028): 100,231M KRW
- • Discount Rate for Issuance Price: 10%
AI Analysis Summary
OliX Pharmaceuticals has filed an amendment to its paid-in capital increase report. The number of new common shares to be issued has been revised down to 670,000 shares from 740,367 shares, leading to a reduction in operating funds raised to 100,231,330,000 KRW from 110,758,162,833 KRW. The primary use of funds remains R&D expenses, with 100,231M KRW allocated for 2026-2028. The listing date for new shares has been moved up to July 15, 2026. The change is due to a revised payment schedule for one of the third-party allocators, BOLD (Business Opportunities for L'Oreal Development), which will no longer participate in this specific allocation. The dilution impact is slightly reduced due to fewer shares being issued, but the overall purpose of funding R&D remains. The issuance price is determined with a 10% discount rate.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.